Company intelligence / Profile preview

Seven and Eight Biopharmaceuticals Inc.

Edison, New Jersey, United Stateslinkedin.com ↗

Ownership: Private
Development stage: Phase 2

Overview

BDB001 has shown favorable safety profile in over 150 patients treated in mono- or in combination with anti-PD-(L)1 therapy, with encouraging clinical responses seen in both mono- and combination therapy in multiple heavily pre-treated tumor types. BDB018, a next-generation TLR7/8 dual agonist, is in Phase 1 trials.

Therapeutic areas: Oncology
Modalities: Small moleculesTLR7/8 dual agonistsToll-like receptor ligand antibody conjugation (TLAC) molecules
Industry: Biotech

Drug pipeline

1 asset

BDB018

Partnerships

Roche (clinical research collaboration for BDB001 and atezolizumab)Eikon Therapeutics (exclusive licensing agreement for TLR7/8 dual agonists)

Beyond the preview

Go deeper on Seven and Eight Biopharmaceuticals Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Seven and Eight Biopharmaceuticals Inc..

Explore the full profile